St. Vincent Hospital
- Type
- Teaching hospital
- Where
- Santa Fe, NM
- Medicare CCN
- 320002
- Received
- $275,253 in 34 records, 2025 ($47,094 general, $228,159 research)
- Source
- CMS Open Payments search ↗
On this site
- Plan sponsor: ST. VINCENT HOSPITAL DBA CHRISTUS ST. VINCENT Fuzzy (name and state)
- Nonprofit: ST VINCENT HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 17 | $47,094 |
| 2025 | Research payment | 17 | $228,159 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Coherus Oncology, Inc. | 4 | $72,525 | 2025 |
| AstraZeneca UK Limited | 1 | $71,750 | 2025 |
| Janssen Research & Development, LLC | 8 | $58,289 | 2025 |
| PFIZER INC. | 8 | $27,866 | 2025 |
| AstraZeneca Pharmaceuticals LP | 3 | $22,727 | 2025 |
| PROGENICS PHARMACEUTICALS, INC. | 1 | $5,175 | 2025 |
| ARRAY BIOPHARMA INC | 1 | $5,000 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $5,000 | 2025 |
| Stryker Corporation | 3 | $4,639 | 2025 |
| Insulet Corporation | 3 | $2,250 | 2025 |
| Bio-Rad Laboratories, Inc. | 1 | $30 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 17 | $228,159 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 9 | $22,250 |
| Space rental or facility fees (teaching hospital only) | 4 | $20,175 |
| Long term medical supply or device loan | 3 | $4,639 |
| Debt forgiveness | 1 | $30 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Stryker Corporation | $1,935 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | 2025 | |
| 2025-12-31 | Stryker Corporation | $1,935 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | 2025 | |
| 2025-12-31 | Stryker Corporation | $769 | Long term medical supply or device loan | In-kind items and services | Connected OR Hub Device, ENDOSCOPY | 2025 | |
| 2025-12-30 | Janssen Research & Development, LLC | $780 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Rea | 2025 |
| 2025-12-30 | Janssen Research & Development, LLC | $390 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Rea | 2025 |
| 2025-12-26 | Janssen Research & Development, LLC | $16,333 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Dar | 2025 |
| 2025-12-08 | PFIZER INC. | $680 | Research payment | In-kind items and services | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE PF08046054SGNPDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUS | 2025 | |
| 2025-12-08 | PFIZER INC. | $680 | Research payment | In-kind items and services | A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE PF08046054SGNPDL1V VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUS | 2025 | |
| 2025-12-02 | Bio-Rad Laboratories, Inc. | $30 | Debt forgiveness | Cash or cash equivalent | Biotestcell 1 & 2 Device, Antiglobulin test | 2025 | |
| 2025-11-26 | Janssen Research & Development, LLC | $1,560 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Rea | 2025 |
| 2025-11-19 | Insulet Corporation | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-11-10 | Janssen Research & Development, LLC | $134 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Rea | 2025 |
| 2025-11-06 | Coherus Oncology, Inc. | $20,137 | Research payment | Cash or cash equivalent | CHS38802 | 2025 | |
| 2025-11-03 | Janssen Research & Development, LLC | $7,416 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Dar | 2025 |
| 2025-10-10 | Coherus Oncology, Inc. | $21,060 | Research payment | Cash or cash equivalent | CHS11402 | 2025 | |
| 2025-09-19 | PFIZER INC. | $11,506 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF PF06821497 MEVROMETOSTAT WITH ENZALUTAMIDE IN METASTATIC C | 2025 | |
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2025 | |
| 2025-09-08 | PROGENICS PHARMACEUTICALS, INC. | $5,175 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | 2025 | |
| 2025-08-29 | ARRAY BIOPHARMA INC | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-08-29 | PFIZER INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-08-29 | PFIZER INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-08-29 | PFIZER INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-08-29 | PFIZER INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-08-29 | PFIZER INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | 2025 | |
| 2025-08-01 | Bayer Healthcare Pharmaceuticals Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xofigo Drug, Oncology | 2025 | |
| 2025-07-31 | Coherus Oncology, Inc. | $10,477 | Research payment | Cash or cash equivalent | CHS38802 | 2025 | |
| 2025-06-26 | Coherus Oncology, Inc. | $20,850 | Research payment | Cash or cash equivalent | CHS38802 | 2025 | |
| 2025-06-12 | Janssen Research & Development, LLC | $30,375 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Dar | 2025 |
| 2025-06-12 | Janssen Research & Development, LLC | $1,300 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Dar | 2025 |
| 2025-03-05 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-03-03 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OMNIPOD Device, Insulin Pump | 2025 | |
| 2025-02-14 | AstraZeneca UK Limited | $71,750 | Research payment | Cash or cash equivalent | CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestra | 2025 | |
| 2025-01-15 | AstraZeneca Pharmaceuticals LP | $12,727 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination with Tremelimumab Lenv | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Santa Fe, NM, county Santa Fe County, NM, state New Mexico; placed by its city name.
| Measure | Place (city or town) Santa Fe, NM | County Santa Fe County, NM | State New Mexico |
|---|---|---|---|
| Population B01003 | 89,019 | 156,105 | 2,120,246 |
| Population, 2020 census P1 | 87,505 | 154,823 | 2,117,522 |
| Median age B01002 | 46.3 | 48.7 | 39.4 |
| Under 18 B01001 | 16.0% | 16.1% | 21.7% |
| 65 and over B01001 | 26.2% | 28.0% | 19.3% |
| Households B11001 | 41,921 | 70,767 | 837,414 |
| Foreign born B05002 | 15.3% | 12.1% | 9.4% |
| Median household income B19013 | $73,482 | $79,071 | $64,059 |
| Median family income B19113 | $89,585 | $97,273 | $79,556 |
| Per capita income B19301 | $50,299 | $52,207 | $36,218 |
| Poverty rate B17001 | 12.9% | 12.0% | 17.8% |
| Unemployment rate B23025 | 5.1% | 5.3% | 6.0% |
| Civilian labor force B23025 | 46,589 | 76,615 | 975,902 |
| Mean commute (minutes) B08013 | 21.0 | 23.8 | 23.5 |
| Bachelor's degree or higher B15003 | 47.8% | 46.1% | 31.0% |
| Housing units B25001 | 46,608 | 78,834 | 956,964 |
| Owner-occupied B25003 | 63.6% | 71.5% | 70.0% |
| Renters B25003 | 36.4% | 28.5% | 30.0% |
| Median home value B25077 | $444,900 | $446,300 | $248,100 |
| Median gross rent B25064 | $1,463 | $1,389 | $1,067 |
| White, not Hispanic B03002 | 42.5% | 44.0% | 36.0% |
| Black B03002 | 1.1% | 0.8% | 1.8% |
| Hispanic or Latino B03002 | 49.5% | 47.9% | 48.4% |
| Asian B03002 | 1.9% | 1.4% | 1.6% |
| American Indian and Alaska Native B03002 | 1.4% | 2.4% | 8.5% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santa Fe, NM.
Comments